Sun Pharma has announced the launch of its semaglutide injection in India under two new brand names: Noveltreat (for weight management) and Sematrinity (for Type 2 Diabetes). Both products will be available across all strengths, priced significantly lower than the innovator brand to enhance affordability. The launch underscores Sun Pharma’s commitment to addressing the large patient pool suffering from obesity and diabetes in the country.
Sun Pharma Introduces Semaglutide Treatments in India
Sun Pharmaceutical Industries Limited announced on March 21, 2026, the launch of its semaglutide injection in India, marketed under two distinct brand names to target two major public health concerns: obesity and Type 2 Diabetes Mellitus (T2DM).
Product Portfolio and Affordability
The two new products are:
- Noveltreat: Indicated for chronic weight management in adults, to be used alongside diet and exercise. It is available in five dose strengths, ranging from 0.25 mg/0.5 mL up to 2.4 mg/0.75 mL. Weekly therapy costs for Noveltreat range approximately from ₹900 to ₹2,000.
- Sematrinity: Indicated for insufficiently controlled Type 2 Diabetes Mellitus (T2DM) as an adjunct to diet and exercise. It is available in two dose strengths: 2 mg/1.5 mL and 4 mg/3 mL. Weekly therapy costs for Sematrinity range from approximately ₹750 to ₹1,300.
Sun Pharma emphasized that these products are priced significantly lower than the innovator brand, supporting greater affordability for the Indian patient community.
Device Features and Manufacturing
To improve patient compliance and usability:
- Noveltreat utilizes a prefilled pen featuring a concealed needle to ease injection fear and enhance dosing accuracy.
- Sematrinity is offered in a multi-dose pen format allowing for flexible dosing via a smooth dialer.
Both easy-to-use, pre-filled pens were developed by leading global pharmaceutical device suppliers and are manufactured in Europe.
Addressing India’s Health Burden
Kirti Ganorkar, Managing Director, noted the company’s dedication to providing high-quality, affordable therapy. The announcement highlights the critical need for effective treatments, referencing national data:
- The National Family Health Survey-5 (NFHS-5) indicated that almost one in four Indians between the ages of 15-49 is currently overweight or obese.
- The ICMR INDIAB 17 study (2023) estimated that 101.3 million people in India were living with diabetes.
- A significant challenge remains, as approximately 64% of patients in India do not achieve their HbA1c targets.
Sun Pharma is also rolling out a holistic patient support program to guide patients throughout their treatment journey.
About GLP-1 Agonists
GLP-1 receptor agonists, including semaglutide, are considered highly effective therapies for managing T2DM and obesity, offering benefits such as the reduction of cardiovascular and renal morbidity and mortality.
Source: BSE
